ASX: EIQ RELEASE **15 December, 2022**

POSITIVE INTERIM RESULTS FROM

CLINICAL TRIAL AT ST VINCENT'S HOSPITAL

Highlights:

- **Echo IQ's EchoSolv™ successfully identified 100% of patients with Severe Aortic Stenosis within current clinical guidelines**
- **EchoSolv™ identifies an additional group of patients at significantly increased risk of Severe Aortic Stenosis (AS)**
- **EchoSolv™ demonstrated its ability to add value to clinical practice as 45% of patients with guideline-severe AS identified by EchoSolv™ had not been reported as having guideline-severe AS by the cardiologist**

Sydney: AI and Medical Technology company Echo IQ ("the Company") (ASX:EIQ) is pleased to announce positive interim results from its clinical trial at St Vincent's Hospital in Melbourne, Australia. The study demonstrates that the artificial intelligence in Echo's IQ's EchoSolv™ for Aortic Stenosis ("EchoSolv™) enhances the identification of severe aortic stenosis (AS) using echocardiography.

Echo IQ's Chief Medical Advisor, Professor David Playford said: "The EchoSolv™ clinical decision-support platform is the first in the world to show improvement in severe AS identification compared with current clinical practice. We expect the automatic highlighting of patients with the AS phenotype using EchoSolv™ to assist doctors in decision-making for aortic valve intervention and follow-up in a highly consistent, systematic and efficient manner. These interim findings are a significant step towards Echo IQ's goal of saving lives by assisting doctors in finding the right patients, every time, for the right intervention for heart valve disease."

Background

Echo IQ's EchoSolv™ platform for the detection of severe aortic stenosis was applied retrospectively to echocardiography ("echo") data from the hospital. The results of the EchoSolv™ platform were compared with the cardiologist reports and clinical outcomes of patients. The trial's primary objective was to evaluate whether EchoSolv™ could enhance identification of patients with severe AS and help guide doctors to make active management plans for these patients.

Interim Findings

- EchoSolv™ successfully identified 100% of patients with guideline-defined severe aortic stenosis (being 317, or 3.8%, of the study population of 8,257 patients attending the hospital's echo laboratory).

ECHOIQ Limited ABN: 48 142 901 353
+61 2 9159 3719 / www.echoiq.ai
404/309 George Street, Sydney NSW 2000 Australia

- EchoSolv™ showed its capability to enhance clinical practice as 142 (or 45%) of those patients identified with guideline-severe AS by EchoSolv™ had not been identified as having guideline-severe AS by the cardiologist.
- EchoSolv™ identified an additional 145 patients (1.8% of the total study population) with a medium-high probability of severe AS but falling outside current clinical practice guidelines for a severe AS diagnosis. These patients would benefit from further review by the cardiologist.

Interim Conclusions

This study demonstrates the potential for EchoSolv™ to play an important "decision support" role in echo reporting because of the major influence a diagnosis of severe AS has on subsequent management. The echo report issued by the cardiologist has a substantial impact on valve intervention decisions. Where severe AS had been reported by the cardiologist, patients went on to receive aortic valve replacements in 57% of cases. Where the patient had not initially been identified as having disease of this severity by the cardiologist only 23% of cases underwent valve intervention. Severe AS is a serious condition with a high risk of death if left untreated, so identifying all patients with severe AS is of great importance. EchoSolv™ therefore shows strong promise by successfully highlighting all patients with guideline-severe AS to the reporting cardiologist, to assist with decision-making.

Echo IQ expects to release the full results of this study once the additional analysis of a further 42 echo reports is completed and the clinical study being undertaken at sister hospital, St Vincent's Sydney is concluded.

Comments

Echo IQ Executive Chair Andrew Grover said: "Echo IQ recently announced positive study results in the US and the launch of EchoSolv™ for use in the identification of guideline-defined severe aortic stenosis. Now we are pleased to share these impressive interim results from St. Vincent's Hospital in Melbourne. This study shows the accurate identification of all guideline-defined cases of severe AS by EchoSolv™ as well as the identification of an additional group of people at similar risk of mortality from the disease. This reinforces how our platform can play an important role in clinical decision making. We look forward to supporting healthcare professionals achieve better identification of patients at risk and driving forward with the commercial rollout of EchoSolv™."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:
Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:
Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ
Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.